-+ 0.00%
-+ 0.00%
-+ 0.00%

Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial

Benzinga·08/17/2026 06:54:25
Listen to the news
  • Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting
  • Data to be presented at an upcoming medical meeting and shared with global regulatory authorities